LMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lockheed Martin Corp (LMT) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has demonstrated strong financial performance in its latest quarter and has positive growth prospects in the defense sector, the stock appears fairly valued after a significant rally. Additionally, hedge fund selling and neutral insider activity suggest limited immediate upside. The lack of strong trading signals and mixed analyst ratings further support a hold recommendation.
The technical indicators are mixed. The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 43.286, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level of 635.677, with resistance at 666.046. This suggests limited immediate upside potential.
Strong Q4 financial performance with revenue up 9.12% YoY, net income up 155.03% YoY, and EPS up 161.26% YoY.
Record backlog and expected growth in 2026 driven by global demand for defense products.
Positive developments in the defense sector, including increased munitions demand and multi-year missile production arrangements.
Hedge funds are selling, with a 143.99% increase in selling activity last quarter.
Analyst ratings are mixed, with several firms maintaining neutral or hold ratings despite raising price targets.
Concerns over growth uncertainty in key segments (Aeronautics and RMS) and margin risks from evolving contract terms.
No recent congress trading data or significant insider buying to indicate strong confidence in the stock.
In Q4 2025, Lockheed Martin delivered exceptional financial results: Revenue increased by 9.12% YoY to $20.32 billion, net income surged by 155.03% YoY to $1.344 billion, EPS rose by 161.26% YoY to $5.8, and gross margin improved significantly by 208.09% YoY to 11.43. These results highlight strong operational performance and growth momentum.
Analyst ratings are mixed. While several firms raised price targets (e.g., Morgan Stanley to $675, BofA to $660, UBS to $663), most maintain neutral or hold ratings. Concerns include program execution risks, margin pressures, and cash flow headwinds, despite strong demand signals and backlog growth.
